BioTech Medics, Inc. Announces the Closing On the Medical Practice of Charles R. Crane, M.D. and Associates, Inc., Dallas, Texas, Bringing 1.2 Million Dollars of Assets Into the Company
DALLAS, Dec 9, 2004 /PRNewswire-FirstCall via COMTEX/ --
Mr. Keith Houser, CEO of BioTech Medics, Inc. (Pink Sheets: BTMD), a Nevada public corporation announced the closing on the acquisition of the existing medical practice of Charles R. Crane, M.D. and Associates, Inc., Dallas, Texas.

"This is the first of between 75 to 100 medical practices and/or clinics the Company proposes acquiring, franchising and/or affiliating with BioTech Medics," said Mr. Houser. Our goal is to have a minimum of one or more Pain Management & Wellness Centers in each of the top 30 cities in the USA utilizing the proprietary Neurolase 150 Medical Laser device that has FDA Approval to treat "muscle, arthritic and skeletal pain." The acquisition of the medical practice of Charles R. Crane MD and Associates Inc. brings a well-established practice of over 33 years as the flagship model for other BioTech Medic's Pain Management & Wellness Centers.

Dr. Crane stated: "The practice was established in 1971 and has grown over the decades and moved from one location to another in Dallas County. Currently it is at the NorthPoint Medical Center, 12606 Greenville Avenue, Suite 105, Dallas, TX 75243. This is a very convenient Northeast Dallas location just off Interstate 635 (also known locally as LBJ Freeway) and Greenville Avenue just East past the High 5 (Highway 75 Central Expressway) interchange."

Mr. Houser indicated that the practice acquisition brings over $1.2 million in assets into BTMD, with projected gross revenues for 2005 near $1 million. Dr. Crane is a resident of Dallas, Texas, and will also be serving as Medical Director of Charles R. Crane & Associates, Inc. on behalf of BTMD. Dr. Crane is the new President of BioTech Medics. He is a Texas licensed medical doctor and is a board certified specialist in physical medicine and pain management, which is a major component of the new direction of the company.

The BioTech Medics Board will be addressing in specific press releases within the next few weeks what key characteristics the investor should be looking for in BioTech as an investment. Those key characteristics addressed by BTMD will include:

1. Announcements of Strategic mergers, purchases and/or alliances that
will increase the Company's assets (net worth), potential sales and
ultimately earnings.
2. Strategic mergers, purchases and/or alliances that will provide unique
and proprietary products and services immediately to BTMD.
3. Why and how the growth potential for BioTech Medics is excellent due
to the proprietary products and services.
4. The BioTech Medics Board of Directors' goal is to incorporate the
first three key characteristics of the Company specified above so
BTMD can ultimately move up to a major national stock exchange, or
listing as a reporting public corporation as soon as possible.
Medical professionals who would like to be a part of the BioTech Medic's Pain Management & Wellness team, are invited to call Keith Houser, CEO, for a confidential interview.

BioTech Medics, Inc.
222 W. Las Colinas Blvd., Suite 1650E
Irving, TX 75039 USA

Phone: 972-274-5533
Fax: 972-230-4629
Email:
biotechmedics@yahoo.com

Safe Harbor for Forward-Looking Statements.

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the company to complete the planned bridge financing, market conditions, the general acceptance of the Company's products and technologies, competitive actors, timing, and other risks described in the Company's SEC reports and Filings.

SOURCE BioTech Medics, Inc.

Keith Houser, CEO of BioTech Medics, Inc., +1-972-274-5533, or
fax, +1-972-230-4629, or
biotechmedics@yahoo.com

(BTMD)

--------------------------------------------------------------------------------

Copyright (C) 2004 PR Newswire. All rights reserved.